IP Library › Granted Patent US 12697370
Granted Patent B2
US 12697370 · App. 18/555,431 · Granted Aug 4, 2026

PSG1 for use in the treatment of osteoarthritis

Inventors: Tom Moore (Cork, IE); Anthony James Peterson Clover (Cork, IE)
Assignee: UNIVERSITY COLLEGE CORK—NATIONAL UNIVERSITY OF IRELAND, CORK
A61K38/1774A61K9/0019A61P19/02C07K16/3092
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697370
App. No.
18/555,431
Granted
Aug 4, 2026
Kind
B2
Abstract

The use of Fc-tagged Pregnancy-specific glycoprotein 1 (PSG1-Fc) in a method of treatment of osteoarthritis or damaged cartilage in a human, in which the PSG1 is administered by intra-articular injection, is described. Also described is the use of CC49 in a method of treatment of osteoarthritis or damaged cartilage in an equine mammal, in which the CC49 is administered by intra-articular injection. (FIG. 3 A-C) Also described is the use of PSG1 in a method of treatment of wounds, scarring, burns and diabetic ulcers in a mammal.

Claims (6)

1 . A method of treatment of osteoarthritis or damaged cartilage in a human comprising administering a therapeutically effective amount of Pregnancy-specific glycoprotein 1 (PSG1) to the human, by intra-articular injection.

2 . The method of claim 1 , in which the PSG1 is Fc-tagged PSG1 (PSG1-Fc).

3 . The method of claim 1 , in which a PSG1 or PSG1-Fc expression vector is administered to the human.

4 . A method of treatment of osteoarthritis or damaged cartilage in an equine mammal comprising administering a therapeutically effective amount of CC49 to the equine mammal by intra-articular injection.

5 . The method of claim 4 , in which the CC49 is Fc-tagged CC49 (CC49-Fc), and in which the Fc tag is optionally an equine Fc tag.

6 . The method of claim 4 , in which a CC49 or CC49-Fc expression vector is administered to the equine mammal.